Skandinaviska Enskilda Banken Ab (Publ) Invitae Corp Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$2.13 - $9.01 $61,367 - $259,587	-28,811 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$6.28 - $15.59 $89,810 - $222,952	-14,301 Reduced 33.17%	28,811 $230,000
Q3 2021 Nov 10, 2021	BUY	$24.31 - $33.6 $1.05 Million - $1.45 Million	43,112 New	43,112 $1.23 Million
Q1 2021 May 14, 2021	SELL	$33.06 - $56.93 $831,723 - $1.43 Million	-25,158 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$39.09 - $57.4 $363,927 - $534,394	-9,310 Reduced 27.01%	25,158 $1.05 Million

Q3 2020 Nov 12, 2020	BUY	$28.43 - $44.67 $835,557 - $1.31 Million	29,390 Added 578.77%	34,468 $1.49 Million
Q2 2020 Aug 13, 2020	BUY	$11.71 - $30.29 $59,463 - $153,812	5,078 New	5,078 $154,000

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.